European Commission Extends License for the Medication Onglyzatm
The European Commission has granted a license extension for Bristol-Myers Squibb and AstraZeneca's oral anti diabetic medication onglyzatm also known as saxagliptin to include Type 2 diabetics who suffer from moderate to severe renal failure.
Diabetes & Renal Impairment
Doctors estimate that approximately twenty-five percent of diabetics also have renal impairment. Moderate to severe renal impairments limit the options that are available for diabetics to manage their diabetes properly. “Since the dose of saxagliptin should be limited to 2.5mg based upon renal function, patients' renal function should be assessed prior to treatment commencing and, in keeping with routine care, monitored regularly after treatment has been initiated.” Patients with severe renal failure (not quite end stage) should be closely monitored by their doctor. Diabetics who have been diagnosed with end stage renal failure should not be treated with saxagliptin.
Conclusion - Dr. Neil Munro
“According to Dr Neil Munro, Associate Specialist in Diabetes at the Chelsea and Westminster Hospital and a GP in Surrey, "Patients with Type 2 diabetes and renal impairment present a significant challenge for doctors whose treatment choices need to balance efficacy with side effects. Through effective control of blood sugar levels, saxagliptin provides another treatment option in a patient population where few glucose lowering therapies are currently licensed."